Could a bone drug make dense breasts less Cancer-Prone?
NCT ID NCT04067726
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether denosumab, a drug that blocks RANKL signaling, can reduce mammographic breast density in premenopausal women with dense breasts. Dense breasts are a known risk factor for breast cancer. The study involves 210 women who will receive either denosumab or a placebo for one year, along with calcium and vitamin D. The main goal is to see if the drug lowers breast density, which could lead to new prevention strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Denosumab (a drug that blocks RANKL signaling, also used for osteoporosis)
What this could lead to
If it works, this could point toward a new way to prevent breast cancer in high-risk premenopausal women with dense breasts.
What could go wrong
This is an early phase 2 trial with only 210 participants, so results may not apply broadly. Denosumab can cause side effects like low calcium levels and jaw problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENSE BREASTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States